🇺🇸 FDA
Pipeline program

Psilocybin

COMP 104

Phase 3 small_molecule active

Quick answer

Psilocybin for Major Depressive Disorder is a Phase 3 program (small_molecule) at Compass Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
Compass Therapeutics
Indication
Major Depressive Disorder
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials